deltaDOT Announces Manufacturer for 1D Protein/Nucleic Acid Analysis System
News Sep 08, 2005
deltaDOT has announced that Lathrop Engineering has been awarded the manufacturing contract for its first two commercial products, a protein/nucleic acid analysis system and a DNA sequencer. These products are based on deltaDOT's proprietary Label Free Intrinsic Imaging (LFII) technology.
Both the Peregrine Protein/Nucleic Acid analysis system and the Merlin DNA sequencer are designed to offer unrivalled sensitivity, ultra high-speed throughput and low running costs.
Tony Baxter, CEO of deltaDOT said "We are very impressed with Lathrop's manufacturing capabilities and are confident in their ability to deliver high-quality systems with fast delivery times.”
He adds, “Having previously developed a range of biomedical products, including electrophoresis systems, Lathrop understands the stringent tolerances of this business and the requirements of manufacturing precision instrumentation.”
Further he said, “Their technical abilities, industry experience, and short development cycles are all advantages that we can pass on directly to our customers."
deltaDOT's biomolecule detection technique, LFII, is derived from recent innovations in high-energy physics research and their application in modern biochemical analysis.
Unlike conventional techniques, the technology does not require target molecules to be labelled and therefore enables superior data quantification, while reducing throughput times, operating costs and health and safety issues.
"Both the management and engineering teams at Lathrop are tremendously excited to be working with deltaDOT on the Peregrine and Merlin projects," said Bruce Richardson, VP of Engineering for Lathrop.
He adds, "Founded in their background and field knowledge, both in the bioscience and particle physics, deltaDOT has created a core set of technologies that offer immediately recognizable benefits.”
“The ability to detect and quantify unlabelled proteins is a significant accomplishment and immensely important to the research and pharmaceutical development communities.”
Further he said, “This will also provide deltaDOT with a substantial competitive advantage in the biomedical market and we look forward to sharing in their future success."
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018